NTRB Profile
Nutriband Inc. is a pharmaceutical company specializing in the development of transdermal drug delivery systems. The company's primary focus is on creating innovative transdermal products designed to improve patient outcomes and safety. Its lead product in development, AVERSA fentanyl, is an advanced abuse-deterrent transdermal system that offers extended-release fentanyl for managing chronic pain. This product aims to provide a safer alternative for patients requiring continuous opioid therapy, addressing the critical need for effective pain management while minimizing abuse potential.
In addition to AVERSA fentanyl, Nutriband is working on a range of other transdermal products. These include AVERSA buprenorphine, which is designed for pain management and opioid dependency treatment; AVERSA methylphenidate for attention deficit hyperactivity disorder (ADHD); and a transdermal formulation of exenatide for the management of type 2 diabetes. The company is also developing follicle-stimulating hormone (FSH) for infertility treatments, expanding its portfolio to address various therapeutic areas.
Nutriband Inc. has entered into a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. This collaboration focuses on enhancing the safety and efficiency of handling and administering hazardous drugs, further diversifying Nutriband's product offerings and technological capabilities. The partnership underscores Nutriband's commitment to innovation and its strategic approach to expanding its market presence.
Incorporated in 2016 and headquartered in Orlando, Florida, Nutriband Inc. leverages its expertise in transdermal technology to address unmet medical needs and improve patient care. The company's ongoing research and development efforts reflect its dedication to advancing pharmaceutical solutions and contributing to the broader healthcare landscape.
|
